This chapter explores the monopolistic nature of the medical industrial complex and the unethical practices of big pharma. It discusses examples such as the contamination of HIV-tainted drugs and the suppression of affordable HIV treatment options. The chapter also touches on the influence of private industry funding on the FDA and the challenges faced by doctors and patients in building out-of-network medical services.